Cabaletta Bio (NASDAQ:CABA) Given New $16.00 Price Target at Guggenheim

Cabaletta Bio (NASDAQ:CABA) had its price target increased by Guggenheim from $15.00 to $16.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

CABA has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Morgan Stanley cut their target price on shares of Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Cabaletta Bio Stock Down 5.3%

NASDAQ CABA opened at $2.67 on Tuesday. The company has a market cap of $257.01 million, a price-to-earnings ratio of -1.17 and a beta of 3.25. Cabaletta Bio has a twelve month low of $0.99 and a twelve month high of $3.78. The business’s fifty day moving average is $2.87 and its 200 day moving average is $2.55.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Monday, March 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. On average, research analysts anticipate that Cabaletta Bio will post -2.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Steve Gavel purchased 22,170 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The stock was bought at an average price of $2.27 per share, with a total value of $50,325.90. Following the completion of the purchase, the insider owned 22,170 shares in the company, valued at approximately $50,325.90. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Nichtberger acquired 45,000 shares of the stock in a transaction dated Wednesday, January 21st. The shares were bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,031,483 shares of the company’s stock, valued at $2,310,521.92. The trade was a 4.56% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 127,668 shares of company stock valued at $286,211 over the last 90 days. 11.25% of the stock is owned by corporate insiders.

Institutional Trading of Cabaletta Bio

Several institutional investors have recently added to or reduced their stakes in CABA. T. Rowe Price Investment Management Inc. increased its position in Cabaletta Bio by 17.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock valued at $21,590,000 after purchasing an additional 1,495,768 shares during the period. Invesco Ltd. lifted its position in shares of Cabaletta Bio by 54.1% in the 4th quarter. Invesco Ltd. now owns 189,195 shares of the company’s stock worth $414,000 after purchasing an additional 66,395 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of Cabaletta Bio in the 4th quarter worth approximately $58,000. KVP Capital Advisors LP bought a new stake in shares of Cabaletta Bio in the 4th quarter valued at $1,107,000. Finally, Ikarian Capital LLC bought a new stake in shares of Cabaletta Bio in the 4th quarter valued at $1,971,000.

Key Stories Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: Company update says the rese-cel myositis BLA submission remains on track for 2027 based on a 17‑patient single‑arm registrational cohort and includes an outpatient dosing option — a clearer regulator timeline and an outpatient pathway can materially de‑risk and increase the program’s commercial potential. Read More.
• Positive Sentiment: Q4/FY2025 results: EPS of ($0.40) beat consensus ($0.45) — a modest beat that may ease near‑term execution concerns and reduce financing/valuation pressure. Read More.
• Positive Sentiment: Guggenheim raised its price target from $15 to $16 and initiated/maintained a “Buy” view, signaling strong upside vs. the current price and likely supporting positive sentiment among growth investors. Read More.
• Neutral Sentiment: An analyst roundup (TipRanks/Globe and Mail) discussed CABA among other healthcare names — useful for context but not a direct catalyst. Read More.
• Negative Sentiment: Morgan Stanley lowered its price target from $14 to $13 but kept an “Overweight” rating — the cut in target is a mild negative for near‑term sentiment despite the positive rating stance. Read More.
• Negative Sentiment: Multiple short‑interest alerts say there was a “large increase” in March, but the underlying reported figures are inconsistent (showing 0 shares/NaN changes and 0.0 days‑to‑cover). The headlines alone can spark selling or volatility even though the data appears erroneous — investors should treat these short‑interest claims with caution and await reliable filings. (Multiple market feeds)

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.